Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer

Trial Profile

Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Anastrozole; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin liposomal; Epirubicin; Exemestane; Letrozole; Tamoxifen
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms ADAPT; ADAPT-HR+HER2-
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 25 Sep 2013 New source identified and integrated (German Clinical Trials Register; DRKS00005203).
    • 07 Jun 2013 Trial protocol presented at ASCO 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top